PLX5568 / Roche, Daiichi Sankyo - LARVOL DELTA

Association of HNMT gene polymorphisms with carnosine content in red-brown Korean native chickens. (PubMed, Anim Biosci) - "One synonymous SNP (rs29009298C/T) of the HNMT gene was genotyped by PCR-RFLP methods whereas four missense SNPs (rs734406537G/A; rs736514667A/G; rs15881680G/A and rs316765035T/C) of the HNMT gene, and one missense SNP rs737657949A/C of the HNMT-like gene were genotyped by PACE genotyping technology...This study also reported the sex effect on the carnosine content, where females had more content of carnosine compared to that of male KNC-R. Two SNPs (synonymous: rs735769522C/T) and missense: rs736514667A/G) in the HNMT gene might be used as genetic markers in the selection and breeding of chickens with better taste and high-flavored meat."

Journal

Conservative versus Liberal Oxygenation Targets in Intensive Care Unit Patients (ICONIC): A Randomized Clinical Trial. (PubMed, Am J Respir Crit Care Med) - " Among mechanically ventilated ICU patients with an expected mechanical ventilation duration of at least 24 hours, using a low-oxygenation strategy did not result in a reduction of 28-day mortality compared to a high-oxygenation strategy. Clinical trial registration available at www.who.int/clinical-trials-registry-platform, ID: NTR7376."

Clinical • Journal • Critical care • Infectious Disease • Novel Coronavirus Disease

ICONIC study-conservative versus conventional oxygenation targets in intensive care patients: study protocol for a randomized clinical trial. (PubMed, Trials) - "The ICONIC trial is expected to provide evidence on the effects of conservative versus conventional oxygenation targets in the ICU population. This study may guide targeted oxygen therapy in the future."

Clinical • Journal • Critical care

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. (PubMed, Lancet) - "All study vaccines boosted antibody and neutralising responses after ChAd/ChAd initial course and all except one after BNT/BNT, with no safety concerns. Substantial differences in humoral and cellular responses, and vaccine availability will influence policy choices for booster vaccination."

Clinical • Journal • P2 data • Fatigue • Infectious Disease • Meningococcal Infections • Novel Coronavirus Disease • Pain • Respiratory Diseases